Compare Gemini Space Station Inc (GEMI) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gemini Space Station Inc vs Johnson & Johnson — how do they compare? Gemini Space Station Inc trades at $4.64 (market cap $590.44M), while Johnson & Johnson trades at $249.09 (market cap $594.63B). The key difference: Johnson & Johnson is far larger — about 1007.1× Gemini Space Station Inc's market cap, and Johnson & Johnson pays a 2.17% dividend while Gemini Space Station Inc pays none. Which is the better fit depends on your goals.
| GEMI | JNJ | |
|---|---|---|
Market Cap | $590.44M | $594.63B |
Sector | Technology | Health |
52-Week High | $32.52 | $267.24 |
52-Week Low | $3.91 | $162.98 |
Enterprise Value | $580.43M | $627.57B |
Volume | — | 6,156,228 |
Dividend Yield | — | 2.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gemini Space Station (GEMI) trades at $4.69, up 8.06% in the past 24 hours, with a bullish technical signal but weak fundamentals. The company reported a net loss of $582.81 million in 2025 on $179.57 million revenue, with negative profit margins and cash burn from operations. Recent news includes a $100 million investment from Winklevoss Capital and multiple securities class action lawsuits filed in May-July 2026.
Outlook remains challenged by persistent losses and legal risks, though analyst consensus suggests modest upside to a $5.88 price target. Investment opportunity hinges on execution turnaround, but high operational and litigation risks warrant caution for stock investors.
Johnson & Johnson (JNJ) trades at $253.85, down 1.52% on the day, with a bullish technical signal supported by moving averages. The company reported Q1 2026 earnings of $2.70 per share, beating estimates, and raised its full-year 2026 outlook. Revenue grew 6.6% annually in Q2 2026, driven by strength in Innovative Medicine and new product launches, though MedTech sales slightly missed expectations.
JNJ offers a compelling investment case with a 64-year dividend king status, robust profitability, and raised guidance, but faces risks from patent expirations and competitive pressures. Analyst consensus is bullish with a $281 price target, suggesting ~11% upside, supported by strong institutional confidence and innovation in AI and robotics targeting $100 billion revenue.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gemini Space Station Inc
Gemini Space Station Inc is the parent company of the Gemini crypto ecosystem, founded by Cameron and Tyler Winklevoss. It operates as a regulated digital asset exchange and custodian, providing a platform for individuals and institutions to trade, store, and stake cryptocurrencies while serving as a trusted bridge between legacy finance and the decentralized web.
Read more on GEMI →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
